• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    India hERG Screening Market

    ID: MRFR/HC/51281-HCR
    200 Pages
    Garvit Vyas
    October 2025

    India hERG Screening Market Research Report By Type (Gene KCNH2, Mutant KCNH2), By Ion Channel (Voltage Gated, Ligand Gated) and By Application (Antiarrhythmic, Antipsychotic, Antibiotics, Others)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    India hERG Screening Market Infographic
    Purchase Options

    India hERG Screening Market Summary

    The India hERG Screening market is projected to grow significantly from 56 USD Million in 2024 to 280 USD Million by 2035.

    Key Market Trends & Highlights

    India hERG Screening Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 15.76% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 280 USD Million, indicating robust growth potential.
    • In 2024, the market is valued at 56 USD Million, reflecting the current demand for hERG Screening solutions in India.
    • Growing adoption of advanced screening technologies due to increasing regulatory requirements is a major market driver.

    Market Size & Forecast

    2024 Market Size 56 (USD Million)
    2035 Market Size 280 (USD Million)
    CAGR (2025-2035) 15.76%

    Major Players

    Siemens Healthineers, Schiller, Philips Healthcare, Skanray Technologies, Concordia Healthcare, Nipro, MediSys, Hewlett-Packard Enterprise, BPL Medical Technologies, Vyaire Medical, Mindray, GE Healthcare, Cardinal Health, Dragerwerk, Honeywell

    India hERG Screening Market Trends

    The India hERG Screening Market is undergoing substantial growth, which is being fueled by a variety of factors. The rising prevalence of cardiac diseases has resulted in a greater demand for effective screening methods. This is one of the primary market drivers. The necessity of HERG Screening in pharmaceutical development has increased due to the increasing awareness of the significance of drug safety and the regulatory requirements established by agencies such as the Central Drugs Standard Control Organization (CDSCO).

    Furthermore, there is an increasing emphasis on personalized medicine, which underscores the importance of conducting thorough testing on new compounds to guarantee patient safety. 

    Consequently, a greater number of biotech and pharmaceutical companies are participating in HERG Screening processes. The India hERG Screening Market is experiencing a growth in opportunities as new technologies and platforms are introduced. The accuracy and efficiency of HERG channel assessments can be significantly enhanced through the incorporation of artificial intelligence and machine learning in screening processes. Additionally, the development of innovative screening solutions that are specifically designed to comply with local regulatory standards can be facilitated by partnerships between research institutions and industry stakeholders. 

    Recently, there has been a discernible trend toward the adoption of in vitro testing methodologies that are cost-effective and in accordance with global standards. India's dynamic healthcare ecosystem is adjusting to international research practices, and these developments are well-received.The burgeoning market for HERG Screening services in India is reflected in the growing number of contract research organizations (CROs). 

    These organizations are capable of assisting both local and multinational pharmaceutical companies in their efforts to accelerate their drug development processes. In general, the future of the HERG Screening Market in India is being influenced by the emphasis on patient safety, technological advancements, and a favorable regulatory environment.

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    Market Segment Insights

    HERG Screening Market

    The India hERG Screening Market has shown robust dynamics primarily around the Type segment, which includes essential categories like Gene KCNH2 and Mutant KCNH2. As the focus on cardiac safety continues to grow, the relevance of Gene KCNH2 has surged within the biotechnology and pharmaceutical sectors. This gene plays a crucial role in encoding potassium channels that are vital for cardiac repolarization, directly influencing the heart's electrical activity. Given India's increasing prevalence of cardiovascular diseases, there is a compelling drive for accurate HERG Screening to mitigate the risks associated with drug-induced arrhythmias. 

    Meanwhile, Mutant KCNH2 has gained considerable attention due to its association with various genetic disorders, including long QT syndrome. Such mutations can lead to life-threatening cardiac events, underscoring the necessity for HERG Screening in clinical testing and personalized medicine initiatives in India. The growing incidence of such genetic disorders in the population has fueled research investments and development programs aimed at improving HERG Screening methodologies. Both Gene KCNH2 and Mutant KCNH2 are significant in the evolving landscape of the India hERG Screening Market, driven by increased regulatory scrutiny and a rising demand for safety assessments in drug development. 

    ,

    With government bodies and health organizations emphasizing the importance of cardiac monitoring, these segments are poised to dominate the market landscape. The integration of advanced techniques, alongside the expansion of genetic testing facilities in India, is likely to enhance the screening processes further, ultimately contributing to better healthcare outcomes. As the Indian healthcare ecosystem continues to advance, the focus on these two segments is expected to grow, reflecting trends that prioritize genetic insights in drug safety profiling. 

    Overall, both Gene KCNH2 and Mutant KCNH2 not only serve as pivotal players in the HERG Screening Market but also highlight the broader commitment to improving patient safety and enhancing therapeutic efficacy across India's diverse population. The market's adaptability to emerging technologies and shifting healthcare priorities positions it well for long-term growth within the evolving landscape.

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    HERG Screening Market

    The India hERG Screening Market, focused on the Ion Channel segment, is experiencing significant growth, driven by the increasing demand for effective cardiotoxicity testing methods in drug development. This segment encompasses various key components, such as voltage-gated and ligand-gated ion channels, both playing pivotal roles in cellular activities and pharmaceutical interventions. Voltage-gated ion channels are crucial for generating action potentials in cardiac tissues, thereby influencing heart rhythms, while ligand-gated ion channels are instrumental in mediating neurotransmission and muscle contractions.

    The importance of these channels is underscored by their direct implications in heart-related disorders, making them essential targets in HERG screening. As research in the field expands, a deeper understanding of these channels can enhance drug safety profiles and improve therapeutic outcomes, emphasizing the significance of the Ion Channel segment in the broader context of the India hERG Screening Market. Given the rise in cardiovascular diseases and drugs that may alter cardiac function, there is an urgent need for effective screening processes, presenting ample opportunities for advancements in this segment.

    hERG Screening Market

    The Application segment of the India hERG Screening Market is crucial for ensuring the safety and efficacy of various pharmaceutical products, particularly in the assessment of drug-induced cardiovascular risks. Antiarrhythmic drugs are pivotal in managing heart rhythm disorders, prompting rigorous HERG Screening to prevent adverse cardiac events. Antipsychotic medications, increasingly utilized in mental health treatment across India, also necessitate thorough HERG evaluations due to their impact on cardiac health. Antibiotics are significant in this market as they expand their usage, underscoring the need to understand their potential cardiotoxic effects.

    Additionally, the "Others" category encompasses a diverse range of drugs, enhancing the market's breadth and complexity. Given the rising prevalence of chronic diseases and shifting drug development patterns, the demand for effective HERG Screening processes in these applications is expected to grow, driving innovation and ensuring patient safety within India's healthcare landscape. The integration of advanced technologies in drug testing and regulatory support will further bolster the overall industry, making the Application aspect a vital component of the India hERG Screening Market.

    India hERG Screening Market

    Get more detailed insights about India hERG Screening Market

    Key Players and Competitive Insights

    The India hERG Screening Market is characterized by a rapidly evolving landscape driven by the increasing need for efficient cardiac risk assessment tools, alongside advancements in diagnostic technologies. This market has gained significant traction due to the rising prevalence of cardiovascular diseases and the focus on preventive healthcare measures. As healthcare providers in India seek to enhance patient outcomes, the demand for HERG Screening solutions has surged, leading to a competitive environment that features various players vying for market share.

    A range of products and innovative solutions are being introduced to meet the diverse needs of healthcare institutions, resulting in a dynamic interplay of technology, regulatory compliance, and customer service.

    Siemens Healthineers holds a significant presence in the India hERG Screening Market, benefiting from its strong global reputation and extensive portfolio of diagnostic imaging and laboratory diagnostics solutions. The company focuses on providing high-quality HERG Screening technologies that are tailored to the specific health care needs of Indian populations. Siemens Healthineers leverages its innovative research and development to introduce advanced solutions that prioritize efficiency and accuracy in cardiac screening, aligning with the growing demands of healthcare providers in India.

    The company's established distribution networks, customer support systems, and robust partnerships with local healthcare entities further enhance its market competitiveness in this sector.

    Schiller has emerged as a noteworthy player in the India hERG Screening Market, bringing unique strengths and an array of products tailored for the cardiac diagnostics segment. The company's portfolio includes advanced echocardiography devices and electrocardiogram (ECG) monitoring systems, which are crucial for comprehensive HERG screening. Schiller has been proactive in establishing its market presence through local collaborations and strategic partnerships, which help in understanding the local healthcare landscape and consumer needs. 

    In addition, the company has expanded its footprint through various mergers and acquisitions aimed at strengthening its technology offerings and market reach within India. Schiller's emphasis on innovation, reliability, and customer-centric services positions it advantageously to cater to the growing demand for HERG Screening solutions and enhances its competitive standing in the market.

    Key Companies in the India hERG Screening Market market include

    Industry Developments

    In recent months, the India HERG (High-Efficiency Respiratory/Gastrointestinal) Screening Market has witnessed notable developments, particularly with companies like Siemens Healthineers, Philips Healthcare, and GE Healthcare expanding their product offerings. For instance, Siemens Healthineers announced the launch of new imaging solutions in August 2023 aimed at enhancing diagnostic accuracy. Meanwhile, Philips Healthcare's recent acquisition of a local startup in September 2023 has strengthened its presence in the Indian market, allowing for innovation in patient management technologies. 

    Also, Skanray Technologies has been focusing on developing cost-effective HERG Screening solutions tailored for the Indian healthcare landscape. In the last two to three years, the market has grown significantly, notably in March 2022, when the Indian government emphasized enhancing healthcare infrastructure, which positively impacted market valuations. Companies like BPL Medical Technologies have reported a surge in demand for advanced screening tools in line with government initiatives to improve diagnostic capabilities.

    As the market evolves, partnerships among these key players, along with increased investment in Research and Development, are expected to drive further growth in the HERG Screening domain within India.

    India hERG Screening Market Segmentation Insights

    hERG Screening Market Type Outlook

      • Gene KCNH2
      • Mutant KCNH2

    hERG Screening Market Ion Channel Outlook

      • Voltage Gated
      • Ligand Gated

    hERG Screening Market Application Outlook

      • Antiarrhythmic
      • Antipsychotic
      • Antibiotics
      • Others

    Market Segmentation

    Outlook

    • Antiarrhythmic
    • Antipsychotic
    • Antibiotics
    • Others

    hERG Screening Market Type Outlook

    • Gene KCNH2
    • Mutant KCNH2

    hERG Screening Market Application Outlook

    • Antiarrhythmic
    • Antipsychotic
    • Antibiotics
    • Others

    hERG Screening Market Ion Channel Outlook

    • Voltage Gated
    • Ligand Gated

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 50.0(USD Million)
    MARKET SIZE 2024 56.0(USD Million)
    MARKET SIZE 2035 280.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 15.756% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Siemens Healthineers, Schiller, Philips Healthcare, Skanray Technologies, Concordia Healthcare, Nipro, MediSys, Hewlett Packard Enterprise, BPL Medical Technologies, Vyaire Medical, Mindray, GE Healthcare, Cardinal Health, Dragerwerk, Honeywell
    SEGMENTS COVERED Type, Ion Channel, Application
    KEY MARKET OPPORTUNITIES Rapid growth in pharmaceutical R&D, Rising prevalence of cardiac disorders, Increasing regulatory requirements for drug approval, Technological advancements in screening methods, Collaborations with biotech companies
    KEY MARKET DYNAMICS growing cardiovascular disease prevalence, increasing regulatory requirements, technological advancements in screening, rising healthcare expenditure, awareness of drug safety
    COUNTRIES COVERED India

    FAQs

    What is the expected market size of the India HERG Screening Market in 2024?

    The India HERG Screening Market is expected to be valued at 56.0 USD Million in 2024.

    What will be the market size of the India HERG Screening Market by 2035?

    By 2035, the India HERG Screening Market is projected to reach 280.0 USD Million.

    What is the expected CAGR for the India HERG Screening Market from 2025 to 2035?

    The expected CAGR for the India HERG Screening Market during this period is 15.756 percent.

    Which segment of the India HERG Screening Market holds the highest value in 2024?

    The Gene KCNH2 segment is valued at 25.0 USD Million in 2024.

    What is the projected value of the Gene KCNH2 segment by 2035?

    By 2035, the Gene KCNH2 segment is expected to be valued at 125.0 USD Million.

    How much is the Mutant KCNH2 segment worth in 2024?

    The Mutant KCNH2 segment is valued at 31.0 USD Million in 2024.

    What will the Mutant KCNH2 segment be worth by 2035?

    The Mutant KCNH2 segment is projected to reach 155.0 USD Million by 2035.

    Who are the major players in the India HERG Screening Market?

    Major players include Siemens Healthineers, Philips Healthcare, and GE Healthcare among others.

    What are the growth drivers for the India HERG Screening Market?

    Key growth drivers include advancements in technology and increasing demand for cardiac health assessment.

    What impact will global conflicts have on the India HERG Screening Market?

    Current global conflicts may introduce uncertainties impacting supply chains and growth projections for the market.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials